TrueBlue Reports Continued Net Loss, Margin Contraction, and $18.4M Asset Impairment in Challenging Year
TBI sits 17% above its 52-week low of $3.45.
Summary
TrueBlue, Inc. filed its annual 10-K, reporting a net loss of $48.0 million for fiscal 2025, a 310 basis point contraction in gross profit margin, and an $18.4 million asset impairment. The filing also details the recent credit facility amendment and ongoing shareholder activism.
Key Events · Earnings and Guidance · TBI
-
Annual Net Loss Reported
TrueBlue reported a net loss of $48.0 million for fiscal year 2025, an improvement from the $125.7 million net loss in 2024, but still indicating ongoing operational challenges.
-
Gross Profit Margin Contracts Significantly
Gross profit as a percentage of revenue decreased by 310 basis points to 22.8% in 2025, primarily due to a shift towards lower-margin staffing businesses and less favorable workers' compensation reserve adjustments.
-
Substantial Asset Impairment Charge
The company recorded an $18.4 million non-cash impairment charge on right-of-use and other long-lived assets, related to a sublease of its Chicago support center as part of a shift to a remote/hybrid work model.
-
Credit Facility Amended and Reduced
The filing confirms the January 30, 2026, amendment to its revolving credit facility, reducing the line of credit from $255 million to $175 million and converting it to an asset-based lending facility, reflecting tighter financial conditions. This event was previously disclosed on 2026-02-03.
Analysis · TBI · Trade & Services
TrueBlue, Inc.'s annual 10-K filing reveals a company grappling with significant financial and corporate governance challenges. While the net loss for fiscal 2025 improved compared to the prior year, the continued losses and a notable 310 basis point contraction in gross profit margin highlight ongoing operational pressures. The substantial $18.4 million non-cash impairment charge on long-lived assets, driven by a shift to remote work, indicates significant restructuring costs. The report also confirms the recent amendment to its credit facility, which reduces borrowing capacity and shifts to asset-based lending, signaling a tighter financial environment. This comprehensive annual report provides critical details on the company's financial health and strategic responses amidst a backdrop of shareholder activism and a defensive 'poison pill' measure, reinforcing the challenges TBI faces in improving profitability and shareholder value.
At the time of this filing, TBI was trading at $4.05 on NYSE in the Trade & Services sector, with a market capitalization of approximately $135.3M. The 52-week trading range was $3.45 to $7.86. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.